NICE fails to en­dorse Roche's Tecen­triq for breast can­cer; Eli­cio clos­es fi­nanc­ing round with $33M

→ UK’s cost-ef­fec­tive­ness watch­dog NICE is not back­ing Roche‘s PD-L1 check­point in­hibitor Tecen­triq (known chem­i­cal­ly as ate­zolizum­ab), in an­oth­er blow to the Swiss drug­mak­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER